- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mike Lattanzi: Precision Oncology Options and Increasing Rates of Prostate Cancer
Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.
Mike Lattanzi, MD, genitourinary medical oncologist at Texas Oncology, discusses the use of next-generation sequencing when treating an increasing number of patients with genitourinary diseases.
Transcript
Is payer coverage for genomic testing keeping pace with the precision oncology options in genitourinary disease?
I'm fortunate enough to be able to send next-generation sequencing on virtually all of my patients with metastatic disease. And I routinely send both tissue-based as well as liquid cell-free DNA next-generation sequencing for all patients with metastatic GU [genitourinary] cancers.
The most recent annual report on cancer statistics from the American Cancer Society showed a rise in prostate cancer after years of decline. What are your thoughts on why prostate cancer is increasing?
There's recently been an increase in the incidence of prostate cancer diagnoses as well as a trend toward later-stage diagnoses, which a lot of us feel is due to diminished screening during the COVID-19 pandemic. So, these data are just a reminder to always be screening patients in a guideline-appropriate fashion moving forward.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
